-
Jul 16, 2024 | 
cancernetwork.com | Laura W. Goff
Treatment options have expanded over the past few decades across many cancer types. Although these advances provide new opportunities for patients, they also pose new challenges for treatment sequencing for providers. In this article, Laura Goff, MD, MSCI, MMHC, discusses the current state and future directions of treatment sequencing in lower gastrointestinal (GI) cancers.
-
Jun 23, 2023 | 
mdpi.com | Justin Lo |Rajiv Agarwal |Laura W. Goff |Thatcher Heumann
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReviewbyJustin H. Lo, Rajiv Agarwal, Laura W. Goff and Thatcher R. Heumann * Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA*Author to whom correspondence should be addressed.
-
Jun 20, 2023 | 
onclive.com | Milind M. Javle |Laura W. Goff
What is the Role of Biomarker Testing in Biliary Tract Cancers? Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.
-
Jun 20, 2023 | 
onclive.com | Milind M. Javle |Laura W. Goff
Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.
-
May 16, 2023 | 
onclive.com | Laura W. Goff
Laura Goff, MD, associate professor of Medicine, Hematology/Oncology, executive medical director, Vanderbilt-Ingram Cancer Center Patient Care Center, co-chair, Data and Safety Monitoring Committee, Vanderbilt-Ingram Cancer Center, discusses the investigation of adjuvant atezolizumab (Tecentriq) plus bevacizumab (Avastin) in hepatocellular carcinoma (HCC).
-
May 12, 2023 | 
onclive.com | Laura W. Goff
Laura Goff, MD, associate professor of Medicine, Hematology/Oncology, executive medical director, Vanderbilt-Ingram Cancer Center Patient Care Center, co-chair, Data and Safety Monitoring Committee, Vanderbilt-Ingram Cancer Center, discusses the key takeaways from results of the phase 3 SWOG 1815 trial (NCT03768414) in newly diagnosed patients with advanced biliary tract cancers.
-
May 2, 2023 | 
cco.amegroups.com | Michael LaPelusa |Laura W. Goff
The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader). Alternatively, you can also download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link below. If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.
-
May 1, 2023 | 
cco.amegroups.com | Michael LaPelusa |Laura W. Goff
The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader). Alternatively, you can also download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link below. If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.
-
Mar 15, 2023 | 
cco.amegroups.com | Michael LaPelusa |Thatcher Heumann |Laura W. Goff |Rajiv Agarwal
Published by AME Publishing Company Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China. Email: [email protected]
